Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Lower Insulin Clearance Parallels a Reduced Insulin Sensitivity in Obese Youths and Is Associated With a Decline in β-Cell Function Over Time.

Galderisi A, Polidori D, Weiss R, Giannini C, Pierpont B, Tricò D, Caprio S.

Diabetes. 2019 Nov;68(11):2074-2084. doi: 10.2337/db19-0120. Epub 2019 Aug 9.

PMID:
31399433
2.

Response to Letter to the Editor: "Hepatic Insulin Extraction in NAFLD Is Related to Insulin Resistance Rather Than Liver Fat Content".

Utzschneider KM, Kahn SE, Polidori DC.

J Clin Endocrinol Metab. 2019 Nov 1;104(11):5251-5252. doi: 10.1210/jc.2019-01301. No abstract available.

PMID:
31225873
3.

Hepatic Insulin Extraction in NAFLD Is Related to Insulin Resistance Rather Than Liver Fat Content.

Utzschneider KM, Kahn SE, Polidori DC.

J Clin Endocrinol Metab. 2019 May 1;104(5):1855-1865. doi: 10.1210/jc.2018-01808.

4.

Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes.

Cusi K, Bril F, Barb D, Polidori D, Sha S, Ghosh A, Farrell K, Sunny NE, Kalavalapalli S, Pettus J, Ciaraldi TP, Mudaliar S, Henry RR.

Diabetes Obes Metab. 2018 Nov 16. doi: 10.1111/dom.13584. [Epub ahead of print]

PMID:
30447037
5.

Dissection of hepatic versus extra-hepatic insulin clearance: Ethnic differences in childhood.

Piccinini F, Polidori DC, Gower BA, Fernandez JR, Bergman RN.

Diabetes Obes Metab. 2018 Dec;20(12):2869-2875. doi: 10.1111/dom.13471. Epub 2018 Aug 20.

6.

Quantitative path to deep phenotyping: Possible importance of reduced hepatic insulin degradation to type 2 diabetes mellitus pathogenesis.

Bergman RN, Piccinini F, Asare Bediako I, Kabir M, Kolka C, Polidori D, Ader M.

J Diabetes. 2018 Oct;10(10):778-783. doi: 10.1111/1753-0407.12794. Epub 2018 Jul 2. No abstract available.

PMID:
29961982
7.

Potent Sodium/Glucose Cotransporter SGLT1/2 Dual Inhibition Improves Glycemic Control Without Marked Gastrointestinal Adaptation or Colonic Microbiota Changes in Rodents.

Du F, Hinke SA, Cavanaugh C, Polidori D, Wallace N, Kirchner T, Jennis M, Lang W, Kuo GH, Gaul MD, Lenhard J, Demarest K, Ajami NJ, Liang Y, Hornby PJ.

J Pharmacol Exp Ther. 2018 Jun;365(3):676-687. doi: 10.1124/jpet.118.248575. Epub 2018 Apr 19.

PMID:
29674332
8.

Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin.

Polidori D, Iijima H, Goda M, Maruyama N, Inagaki N, Crawford PA.

Diabetes Obes Metab. 2018 May;20(5):1321-1326. doi: 10.1111/dom.13224. Epub 2018 Feb 14.

9.

Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes.

Tamborlane WV, Polidori D, Argenti D, Di Prospero NA.

Pediatr Diabetes. 2018 Jun;19(4):649-655. doi: 10.1111/pedi.12626. Epub 2017 Dec 22.

PMID:
29271103
10.

Hepatic but Not Extrahepatic Insulin Clearance Is Lower in African American Than in European American Women.

Piccinini F, Polidori DC, Gower BA, Bergman RN.

Diabetes. 2017 Oct;66(10):2564-2570. doi: 10.2337/db17-0413. Epub 2017 Jul 14.

11.

Dynamic population pharmacokinetic-pharmacodynamic modelling and simulation supports similar efficacy in glycosylated haemoglobin response with once or twice-daily dosing of canagliflozin.

de Winter W, Dunne A, de Trixhe XW, Devineni D, Hsu CH, Pinheiro J, Polidori D.

Br J Clin Pharmacol. 2017 May;83(5):1072-1081. doi: 10.1111/bcp.13180. Epub 2017 Jan 31.

12.

How Strongly Does Appetite Counter Weight Loss? Quantification of the Feedback Control of Human Energy Intake.

Polidori D, Sanghvi A, Seeley RJ, Hall KD.

Obesity (Silver Spring). 2016 Nov;24(11):2289-2295. doi: 10.1002/oby.21653.

13.

Standardized Mixed-Meal Tolerance and Arginine Stimulation Tests Provide Reproducible and Complementary Measures of β-Cell Function: Results From the Foundation for the National Institutes of Health Biomarkers Consortium Investigative Series.

Shankar SS, Vella A, Raymond RH, Staten MA, Calle RA, Bergman RN, Cao C, Chen D, Cobelli C, Dalla Man C, Deeg M, Dong JQ, Lee DS, Polidori D, Robertson RP, Ruetten H, Stefanovski D, Vassileva MT, Weir GC, Fryburg DA; Foundation for the National Institutes of Health β-Cell Project Team.

Diabetes Care. 2016 Sep;39(9):1602-13. doi: 10.2337/dc15-0931. Epub 2016 Jul 12.

14.

Hepatic and Extrahepatic Insulin Clearance Are Differentially Regulated: Results From a Novel Model-Based Analysis of Intravenous Glucose Tolerance Data.

Polidori DC, Bergman RN, Chung ST, Sumner AE.

Diabetes. 2016 Jun;65(6):1556-64. doi: 10.2337/db15-1373. Epub 2016 Mar 18.

15.

Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants.

Devineni D, Polidori D, Curtin C, Stieltjes H, Tian H, Wajs E.

Clin Ther. 2016 Jan 1;38(1):89-98.e1. doi: 10.1016/j.clinthera.2015.11.008. Epub 2015 Dec 11.

PMID:
26687552
16.

Apparent subadditivity of the efficacy of initial combination treatments for type 2 diabetes is largely explained by the impact of baseline HbA1c on efficacy.

Polidori D, Capuano G, Qiu R.

Diabetes Obes Metab. 2016 Apr;18(4):348-54. doi: 10.1111/dom.12615. Epub 2016 Jan 25.

17.

Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside.

Mudaliar S, Polidori D, Zambrowicz B, Henry RR.

Diabetes Care. 2015 Dec;38(12):2344-53. doi: 10.2337/dc15-0642. Review.

PMID:
26604280
18.

Glycaemic efficacy of canagliflozin is largely independent of baseline β-cell function or insulin sensitivity.

Matthews DR, Zinman B, Tong C, Meininger G, Polidori D.

Diabet Med. 2016 Dec;33(12):1744-1747. doi: 10.1111/dme.13033. No abstract available.

PMID:
26600115
19.

Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin.

Bilezikian JP, Watts NB, Usiskin K, Polidori D, Fung A, Sullivan D, Rosenthal N.

J Clin Endocrinol Metab. 2016 Jan;101(1):44-51. doi: 10.1210/jc.2015-1860. Epub 2015 Nov 18.

20.

Effect of canagliflozin on liver function tests in patients with type 2 diabetes.

Leiter LA, Forst T, Polidori D, Balis DA, Xie J, Sha S.

Diabetes Metab. 2016 Feb;42(1):25-32. doi: 10.1016/j.diabet.2015.10.003. Epub 2015 Nov 11.

PMID:
26575250
21.

Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes.

Henry RR, Thakkar P, Tong C, Polidori D, Alba M.

Diabetes Care. 2015 Dec;38(12):2258-65. doi: 10.2337/dc15-1730. Epub 2015 Oct 20.

PMID:
26486192
22.

Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.

Rosenthal N, Meininger G, Ways K, Polidori D, Desai M, Qiu R, Alba M, Vercruysse F, Balis D, Shaw W, Edwards R, Bull S, Di Prospero N, Sha S, Rothenberg P, Canovatchel W, Demarest K.

Ann N Y Acad Sci. 2015 Nov;1358:28-43. doi: 10.1111/nyas.12852. Epub 2015 Aug 25. Review.

PMID:
26305874
23.

Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects.

Chen X, Hu P, Vaccaro N, Polidori D, Curtin CR, Stieltjes H, Sha S, Weiner S, Devineni D.

Clin Ther. 2015 Jul 1;37(7):1483-1492.e1. doi: 10.1016/j.clinthera.2015.04.015. Epub 2015 Jun 3.

PMID:
26048186
24.

Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor.

Devineni D, Polidori D.

Clin Pharmacokinet. 2015 Oct;54(10):1027-41. doi: 10.1007/s40262-015-0285-z. Review.

PMID:
26041408
25.

Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants.

Devineni D, Polidori D, Curtin CR, Murphy J, Wang SS, Stieltjes H, Wajs E.

Int J Clin Pharmacol Ther. 2015 Jun;53(6):438-46. doi: 10.5414/CP202324.

PMID:
25907176
26.

Determination of the renal threshold for glucose excretion in Familial Renal Glucosuria.

Aires I, Fila M, Polidori D, Santos AR, Costa AB, Calado J.

Nephron. 2015;129(4):300-4. doi: 10.1159/000381677. Epub 2015 Apr 18.

PMID:
25896487
27.

Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes.

Cefalu WT, Stenlöf K, Leiter LA, Wilding JP, Blonde L, Polidori D, Xie J, Sullivan D, Usiskin K, Canovatchel W, Meininger G.

Diabetologia. 2015 Jun;58(6):1183-7. doi: 10.1007/s00125-015-3547-2. Epub 2015 Mar 27.

28.

Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on C-peptide kinetics.

Polidori D, Sha S, Heise T, Natarajan J, Artis E, Wang SS, Vaccaro N, Rothenberg P, Stirban A.

Clin Pharmacol Drug Dev. 2015 Jan;4(1):12-7. doi: 10.1002/cpdd.115. Epub 2014 May 28.

PMID:
27127999
29.

Single- and multiple-dose pharmacokinetics and pharmacodynamics of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants.

Devineni D, Vaccaro N, Polidori D, Stieltjes H, Wajs E.

Int J Clin Pharmacol Ther. 2015 Feb;53(2):129-38. doi: 10.5414/CP202218.

PMID:
25500487
30.

Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study.

Sha S, Polidori D, Farrell K, Ghosh A, Natarajan J, Vaccaro N, Pinheiro J, Rothenberg P, Plum-Mörschel L.

Diabetes Obes Metab. 2015 Feb;17(2):188-97. doi: 10.1111/dom.12418. Epub 2015 Jan 5.

31.

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.

Sha S, Devineni D, Ghosh A, Polidori D, Hompesch M, Arnolds S, Morrow L, Spitzer H, Demarest K, Rothenberg P.

PLoS One. 2014 Sep 30;9(9):e110069. doi: 10.1371/journal.pone.0110069. eCollection 2014.

32.

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.

Sha S, Devineni D, Ghosh A, Polidori D, Hompesch M, Arnolds S, Morrow L, Spitzer H, Demarest K, Rothenberg P.

PLoS One. 2014 Aug 28;9(8):e105638. doi: 10.1371/journal.pone.0105638. eCollection 2014.

33.

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial.

Stein P, Berg JK, Morrow L, Polidori D, Artis E, Rusch S, Vaccaro N, Devineni D.

Metabolism. 2014 Oct;63(10):1296-303. doi: 10.1016/j.metabol.2014.07.003. Epub 2014 Jul 9.

34.

Optimal back-extrapolation method for estimating plasma volume in humans using the indocyanine green dilution method.

Polidori D, Rowley C.

Theor Biol Med Model. 2014 Jul 22;11:33. doi: 10.1186/1742-4682-11-33.

35.

Effects of meal size on the release of GLP-1 and PYY after Roux-en-Y gastric bypass surgery in obese subjects with or without type 2 diabetes.

Yan W, Polidori D, Yieh L, Di J, Wu X, Moreno V, Li L, Briscoe CP, Shankley N, Dohm GL, Pories WJ.

Obes Surg. 2014 Nov;24(11):1969-74. doi: 10.1007/s11695-014-1316-9.

PMID:
24972682
36.

Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.

Sha S, Polidori D, Heise T, Natarajan J, Farrell K, Wang SS, Sica D, Rothenberg P, Plum-Mörschel L.

Diabetes Obes Metab. 2014 Nov;16(11):1087-95. doi: 10.1111/dom.12322. Epub 2014 Jul 8.

PMID:
24939043
37.

Alteration of the glucagon axis in GPR120 (FFAR4) knockout mice: a role for GPR120 in glucagon secretion.

Suckow AT, Polidori D, Yan W, Chon S, Ma JY, Leonard J, Briscoe CP.

J Biol Chem. 2014 May 30;289(22):15751-63. doi: 10.1074/jbc.M114.568683. Epub 2014 Apr 17.

38.

Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.

Devineni D, Vaccaro N, Polidori D, Rusch S, Wajs E.

Clin Ther. 2014 May;36(5):698-710. doi: 10.1016/j.clinthera.2014.02.022. Epub 2014 Apr 13.

39.

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes.

Polidori D, Mari A, Ferrannini E.

Diabetologia. 2014 May;57(5):891-901. doi: 10.1007/s00125-014-3196-x. Epub 2014 Mar 1.

40.

Impaired decline in renal threshold for glucose during pregnancy - a possible novel mechanism for gestational diabetes mellitus.

Klein P, Polidori D, Twito O, Jaffe A.

Diabetes Metab Res Rev. 2014 Feb;30(2):140-5. doi: 10.1002/dmrr.2474.

PMID:
24106177
41.

Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.

Devineni D, Curtin CR, Polidori D, Gutierrez MJ, Murphy J, Rusch S, Rothenberg PL.

J Clin Pharmacol. 2013 Jun;53(6):601-10. doi: 10.1002/jcph.88. Epub 2013 May 14.

42.

Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus.

Polidori D, Sha S, Ghosh A, Plum-Mörschel L, Heise T, Rothenberg P.

J Clin Endocrinol Metab. 2013 May;98(5):E867-71. doi: 10.1210/jc.2012-4205. Epub 2013 Apr 12.

43.

Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study.

Polidori D, Sha S, Mudaliar S, Ciaraldi TP, Ghosh A, Vaccaro N, Farrell K, Rothenberg P, Henry RR.

Diabetes Care. 2013 Aug;36(8):2154-61. doi: 10.2337/dc12-2391. Epub 2013 Feb 14.

44.

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.

Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, Capuano G, Canovatchel W; Canagliflozin DIA 2001 Study Group.

Diabetes Care. 2012 Jun;35(6):1232-8. doi: 10.2337/dc11-1926. Epub 2012 Apr 9.

45.

Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models.

Liang Y, Arakawa K, Ueta K, Matsushita Y, Kuriyama C, Martin T, Du F, Liu Y, Xu J, Conway B, Conway J, Polidori D, Ways K, Demarest K.

PLoS One. 2012;7(2):e30555. doi: 10.1371/journal.pone.0030555. Epub 2012 Feb 15.

46.

Pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-38431055, a novel GPR119 receptor agonist and potential antidiabetes agent, in healthy male subjects.

Katz LB, Gambale JJ, Rothenberg PL, Vanapalli SR, Vaccaro N, Xi L, Polidori DC, Vets E, Sarich TC, Stein PP.

Clin Pharmacol Ther. 2011 Nov;90(5):685-92. doi: 10.1038/clpt.2011.169. Epub 2011 Oct 5.

PMID:
21975348
47.

Roux-en-Y gastric bypass corrects hyperinsulinemia implications for the remission of type 2 diabetes.

Reed MA, Pories WJ, Chapman W, Pender J, Bowden R, Barakat H, Gavin TP, Green T, Tapscott E, Zheng D, Shankley N, Yieh L, Polidori D, Piccoli SP, Brenner-Gati L, Dohm GL.

J Clin Endocrinol Metab. 2011 Aug;96(8):2525-31. doi: 10.1210/jc.2011-0165. Epub 2011 May 18.

PMID:
21593117
48.

Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects.

Sha S, Devineni D, Ghosh A, Polidori D, Chien S, Wexler D, Shalayda K, Demarest K, Rothenberg P.

Diabetes Obes Metab. 2011 Jul;13(7):669-72. doi: 10.1111/j.1463-1326.2011.01406.x.

PMID:
21457428
49.

Ten weeks of rapid ventricular pacing creates a long-term model of left ventricular dysfunction.

Patel HJ, Pilla JJ, Polidori DJ, Pusca SV, Plappert TA, Sutton MS, Lankford EB, Acker MA.

J Thorac Cardiovasc Surg. 2000 Apr;119(4 Pt 1):834-41.

50.

Cardiovascular effects of inhaled nitric oxide in a canine model of cardiomyopathy.

Loh E, Lankford EB, Polidori DJ, Doering-Lubit EB, Hanson CW, Acker MA.

Ann Thorac Surg. 1999 May;67(5):1380-5.

PMID:
10355416

Supplemental Content

Loading ...
Support Center